

NEXT-GENERATION BIOTECH SOLUTIONS

Transforming scientific discoveries into breakthrough therapies for cancer and infectious diseases.



swissrockets

HE | Basel, Switzerland | info@swissrockets.com

Europe's leading biotech incubator identifying breakthrough startups in cancer and infectious diseases



Building The Next Generation Of Biotech Companies, From Discovery To Patient Impact.

Swiss Rockets AG is a European biotech incubator and accelerator focused on identifying, building, and scaling innovative life science companies. Headquartered in Basel, Switzerland, Swiss Rockets brings together scientific excellence, industrial expertise, and strategic execution to translate cutting-edge research into clinically and commercially viable therapies.

The group informs, incubates, and advances biotechnology ventures from early scientific validation through clinical development and strategic partnerships. By combining a hands-on operational model with a strong international network, Swiss Rockets accelerates the path from discovery to patient impact.

Core Focus Areas

Swiss Rockets' portfolio is built around three high-impact therapeutic and technology platforms:



Radioligand therapies for solid tumors



First-in-class PI3K/mTOR pathway inhibitors



Next-generation live-attenuated vaccines

These focus areas address major unmet medical needs in oncology and infectious diseases, leveraging differentiated science with strong translational potential.

Rocket Isotopes AG

Securing The Future Supply Of Medical Radioisotopes



Rocket Isotopes AG is a Swiss Rockets subsidiary focused on the **production, purification, and supply of medical radioisotopes**, with a strategic emphasis on Terbium-161.



The company plays a critical role in establishing a reliable and scalable supply chain for next-generation radiotherapeutics. Rocket Isotopes has successfully completed key proof-of-concept milestones for Tb-161 purification and is advancing toward GMP-compliant production in collaboration with academic and industrial partners.



By integrating isotope manufacturing with downstream radiopharmaceutical development, **Rocket Isotopes strengthens the entire value chain for precision oncology.**



Rocket Isotopes

Rocketvax AG

Redefining Vaccines Through Mucosal Immunity

Rocketvax AG pioneers novel intranasal, live-attenuated vaccines designed to induce strong mucosal and systemic immune responses.

Its lead candidate targets respiratory viral infections and aims to provide broader, longer-lasting protection compared to conventional injectable vaccines.

Rocketvax focuses on scalable manufacturing, robust immunogenicity, and needle-free administration, addressing critical challenges in global vaccination strategies.

Torqur AG

Targeted Therapies For Oncology And Dermatology

Torqur AG develops first-in-class inhibitors targeting the PI3K/mTOR pathway, a central signaling axis in cancer and inflammatory skin diseases. Its lead compound, bimiralisib, a brain penetrant dual PI3K/mTOR inhibitor, has been evaluated in multiple clinical studies across solid tumors, hematologic malignancies and dermatology.

A topical formulation of bimiralisib is being developed for actinic keratosis, a common precancerous skin condition, while oral formulations continue to be explored for solid tumors.

Torqur's approach combines molecular precision with patient-centric treatment strategies.



TORQUR
torqur.com



Torpedo Pharmaceuticals AG

Advancing Next-generation Radioligand Therapies

Torpedo Pharmaceuticals AG is a biotech company developing innovative radioligand therapies (RLTs) for the treatment of solid tumors.

The company's platform is centered on Terbium-161 (Tb-161), a next-generation therapeutic radioisotope with unique physical properties that may offer advantages over currently used radionuclides.

Torpedo's lead program targets PSMA-positive prostate cancer, with a robust preclinical data package and preparations underway for first-in-human clinical studies. In parallel, Torpedo is expanding its pipeline to additional solid tumor indications, leveraging the versatility of its radioligand platform.

Torpedo combines advanced radiochemistry, targeted molecular design, and translational oncology expertise to develop highly precise cancer therapies.



ROCKETVAX
rocketvax.com



Torpedo

torpedopharma.com

